TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Patients with HTLV-1-Associated Myelopathy or Tropical Spastic Paraparesis Sought

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

Researchers at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with HTLV-1-associated myelopathy or tropical spastic paraparesis (HAM/TSP) for an experimental treatment trial. The study will test an experimental drug's ability to ameliorate the immune dysregulation induced by HTLV-1. Testing of this drug will be carried out in compliance with FDA guidelines.

Eligible patients must be at least 16 years of age, meet diagnostic criteria for HAM/TSP, and be negative for HIV, HCV, and hepatitis B surface antigen. The studies will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.

For more information, physicians should send a referral letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP, Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: eatonj@ninds.nih.gov.